Your browser doesn't support javascript.
loading
La deshidroepiandrosterona inhibe a monoamino oxidasa: implicaciones para la depresión y el Parkinson / Dehydroepiandrosterone inhibits monoamine oxidase: implications for depression and Parkinson
Pérez-Neri, Iván.
Affiliation
  • Pérez-Neri, Iván; Instituto Nacional de Neurología y Neurocirugía. Departamento de Neuroquímica. Laboratorio de Adicciones. La Fama. México
Rev. int. androl. (Internet) ; 15(4): 160-164, oct.-dic. 2017. ilus
Article in Spanish | IBECS | ID: ibc-166862
Responsible library: ES1.1
Localization: BNCS
RESUMEN
La concentración de deshidroepiandrosterona (DHEA) se reduce durante el envejecimiento y se asocia con la pérdida de bienestar. Esto se debe a que la DHEA tiene efecto antidepresivo, mejora la cognición y protege contra la muerte neuronal. Puede sugerirse que restituir en la edad avanzada los niveles de la DHEA que se observan en la juventud podría controlar tanto la depresión como la neurodegeneración. Se ha estudiado el efecto de la DHEA sobre el metabolismo de monoaminas para analizar los mecanismos involucrados en la depresión y la neurodegeneración con énfasis en la enfermedad de Parkinson, que cursa con ambas alteraciones. Los resultados muestran que la DHEA modula 2 de los principales sistemas dopaminérgicos cerebrales. La DHEA inhibe a monoamino oxidasa, lo que representa una oportunidad para intervenir en esta enfermedad pues la inhibición de esta enzima tiene efecto antidepresivo y neuroprotector. Este artículo discute los alcances y limitaciones de dichos hallazgos (AU)
ABSTRACT
Dehydroepiandrosterone (DHEA) concentration is reduced during aging, and is associated with the deterioration of our physical and mental health. This occurs because DHEA has an antidepressant effect, improves cognition and prevents neuronal death. It may therefore be suggested that restoring DHEA levels during aging to those observed in youth might control both depression and neurodegeneration. Thus, the effect of DHEA on monoamine metabolism has been studied in the rat brain, to analyze the underlying mechanisms of depression and neurodegeneration with emphasis in Parkinson disease, since it includes both symptoms. Results show that DHEA modulates 2 of the main dopaminergic systems in the brain. DHEA inhibits both monoamine oxidase (MAO) isoforms (A and B), which represents a therapeutic opportunity for this disease since MAO A inhibition yields an antidepressant effect, while that of MAO B is neuroprotective. This paper discusses the goals and limitations of our findings(AU)
Subject(s)
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Mental Health and Behavioral Disorders / Parkinson Disease Database: IBECS Main subject: Parkinson Disease / Dehydroepiandrosterone / Depression / Neuroprotection / Monoamine Oxidase Inhibitors Limits: Humans / Male Language: Spanish Journal: Rev. int. androl. (Internet) Year: 2017 Document type: Article Institution/Affiliation country: Instituto Nacional de Neurología y Neurocirugía/México
Search on Google
Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Mental Health and Behavioral Disorders / Parkinson Disease Database: IBECS Main subject: Parkinson Disease / Dehydroepiandrosterone / Depression / Neuroprotection / Monoamine Oxidase Inhibitors Limits: Humans / Male Language: Spanish Journal: Rev. int. androl. (Internet) Year: 2017 Document type: Article Institution/Affiliation country: Instituto Nacional de Neurología y Neurocirugía/México
...